A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
1/2期
已完成
NCT05975099
| 适应症 | Lyme Disease |
|---|
| 分期 | 1/2期 |
|---|
| 申办方 | ModernaTX, Inc. |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 807 人 |
|---|
| 干预（药物） | mRNA-1975, mRNA-1982 |
|---|
| 开始日期 | 2023年7月26日 |
|---|
| 完成日期 | 2025年5月30日 |
|---|
| 结果公布日 | 2026年7月30日 |
|---|
摘要
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Up to 7 days after Day 1 injection · Participants
| mRNA-1975 Dose Level 1 | 70 Participants |
|---|
| mRNA-1975 Dose Level 2 | 80 Participants |
|---|
| mRNA-1975 Dose Level 3 | 82 Participants |
|---|
| mRNA-1975 Dose Level 4 | 91 Participants |
|---|
| mRNA-1982 Dose Level 1 | 64 Participants |
|---|
| mRNA-1982 Dose Level 2 | 77 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection
Up to 7 days after Day 57 injection · Participants
| mRNA-1975 Dose Level 1 | 79 Participants |
|---|
| mRNA-1975 Dose Level 2 | 80 Participants |
|---|
| mRNA-1975 Dose Level 3 | 90 Participants |
|---|
| mRNA-1975 Dose Level 4 | 96 Participants |
|---|
| mRNA-1982 Dose Level 1 | 70 Participants |
|---|
| mRNA-1982 Dose Level 2 | 82 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection
Up to 7 days after Day 169 injection · Participants
| mRNA-1975 Dose Level 1 | 81 Participants |
|---|
| mRNA-1975 Dose Level 2 | 87 Participants |
|---|
| mRNA-1975 Dose Level 3 | 81 Participants |
|---|
| mRNA-1975 Dose Level 4 | 92 Participants |
|---|
| mRNA-1982 Dose Level 1 | 76 Participants |
|---|
| mRNA-1982 Dose Level 2 | 82 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。